CDNAHealthcare · Diagnostics & ResearchThe 8 Wall Street analysts covering CareDx, Inc. hold a median 12-month price target of $58 — +7.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores CareDx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (100): The shares have been drifting up relative to others.
Volatility (44): The share price moves around a lot.
Size (31): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CDNA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +7.7% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Sept 2026 | Canaccord Genuity | Initiates | Buy | $65 |
| 6 Aug 2026 | BTIG | Maintains | Buy | $45 → $60 |
| 6 Aug 2026 | BTIG | Maintains | Buy | — |
| 31 July 2026 | HC Wainwright & Co. | Reiterates | Neutral | $46 |
| 31 July 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 16 July 2026 | BTIG | Maintains | Buy | $28 → $45 |
| 16 July 2026 | BTIG | Maintains | Buy | — |
| 29 Apr 2026 | BTIG | Maintains | Buy | $26 → $28 |
| 29 Apr 2026 | BTIG | Maintains | Buy | — |
| 26 Feb 2026 | BTIG | Maintains | Buy | — |
| 25 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 15 Dec 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 6 Nov 2025 | BTIG | Maintains | Buy | — |
| 23 Sept 2025 | BTIG | Reiterates | Buy | — |
| 12 Sept 2025 | BTIG | Reiterates | Buy | — |
| 26 Aug 2025 | William Blair | Initiates | Market Perform | — |
| 8 Aug 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 18 July 2025 | Craig-Hallum | Maintains | Buy | — |
| 5 May 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 5 May 2025 | Stephens & Co. | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CDNA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, CareDx, Inc. returned +264.5% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 29% of US stocks
Cheaper than 21% of US stocks
Cheaper than 15% of US stocks
Cheaper than 1% of US stocks
Higher than 87% of US stocks
Higher than 75% of US stocks
Higher than 86% of US stocks
Higher than 46% of US stocks
Higher than 85% of US stocks
Higher than 87% of US stocks
Higher than 42% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CareDx, Inc. has a market value of $2.8B and an enterprise value of $2.4B.
Revenue in the twelve months to 30 June 2026: $458.1M. The latest quarter grew 52.2% year on year.
Net income over the same four quarters: $111.0M, a 24.2% net margin.
Diluted earnings per share, trailing twelve months: $2.07.
Free cash flow in the twelve months to 30 June 2026: $84.0M.
Trailing P/E: 25.9×; forward P/E: 40.5× — the forward figure prices analyst consensus estimates, not reported earnings.
CareDx, Inc. employs 761 people — $602K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CareDx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights AMGN, BHC, CDNA and CNC as defensive healthcare stock plays amid rising inflation and expectations of a possible Federal Reserve rate hike.
Why it matters — The piece positions CDNA within a group of defensive healthcare names that could be relatively attractive to investors in a rate-hike environment.
Zacks Investment Research highlights CareDx (CDNA) as one of four defensive stock picks amid market volatility driven by rising oil prices and escalating Middle East tensions. CDNA is presented alongside COCO, CHEF, and ASMB as a defensive holding.
Why it matters — CareDx is being singled out as a defensive pick during market turbulence, which could draw attention to the stock from investors seeking stability.
A Zacks Investment Research piece examines how CareDx (CDNA) and Concentra Group (CON) have performed compared to their medical sector so far this year, per the headline. The excerpt notes their relative year-to-date performance against the sector.
Why it matters — For CareDx watchers, this comparison shows where the stock stands relative to its medical sector peers so far this year.
Zacks Investment Research profiles CareDx (CDNA) as a potential top pick for momentum investors, evaluating whether the stock has the qualities needed to be a strong momentum candidate. The article frames CareDx in a favorable light for momentum-focused strategies.
Why it matters — The piece signals that CareDx is being recognized as a momentum stock worth consideration, which could draw attention from momentum-driven investors watching the company.
Zacks Investment Research published an Industry Outlook article highlighting CareDx, BrightSpring, and PACS. CareDx was featured among the companies discussed in this industry review.
Why it matters — A CDNA watcher would want to know that CareDx is being featured in an industry outlook, which places the company within the broader sector analysis.
The 8 Wall Street analysts covering CareDx, Inc. have a median 12-month price target of $58, with estimates ranging from $40 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering CareDx, Inc., 5 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CareDx, Inc. 100 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, CareDx, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +7.7% from the last close, and Ticker Nerd's factor model ranks CareDx, Inc. 100 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CareDx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $65 over the next 12 months.
CareDx, Inc. returned +264.5% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
CareDx, Inc. is a precision medicine diagnostics company focused on transplant care and related specialty services.
The most recent item we track (Zacks Investment Research, 14 Sept 2026): "4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike". Zacks Investment Research highlights AMGN, BHC, CDNA and CNC as defensive healthcare stock plays amid rising inflation and expectations of a possible Federal Reserve rate hike.
CareDx, Inc. is a precision medicine diagnostics company focused on transplant care and related specialty services. CareDx develops and commercializes non-invasive molecular tests, laboratory products, digital tools, and patient support services that help clinicians monitor organ health before and after transplantation. Its portfolio includes testing solutions for kidney, heart, and lung transplant patients, along with HLA typing and other transplant laboratory products used to support donor-recipient matching and post-transplant surveillance. The company also offers workflow software, data analytics, and care-management tools that connect transplant centers, patients, and providers across the care journey. In addition to its core transplant business, CareDx serves specialty oncology and cell therapy markets with precision diagnostics and support solutions. CareDx, Inc. is headquartered in Brisbane, California.
CEO Mr. John Walter Hanna Jr. · 761 employees · United States · https://caredx.com
